fidaxomicin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
aminoglycosides, antibiotics obtained from various Micromonospora 4180 873857-62-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • lipiarmicin
  • lipiarmycin
  • tiacumicin B
  • dificid
  • fidaxomicin
  • dificlir
Fidaxomicin is a fermentation product obtained from the Actinomycete Dactylosporangium aurantiacum. In vitro, fidaxomicin is active primarily against species of clostridia, including Clostridium difficile by inhibiting RNA synthesis by RNA polymerases.
  • Molecular weight: 1058.05
  • Formula: C52H74Cl2O18
  • CLOGP: 7.19
  • LIPINSKI: 4
  • HAC: 18
  • HDO: 7
  • TPSA: 266.66
  • ALOGS: -4.93
  • ROTB: 15

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.40 g O

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
May 27, 2011 FDA CUBIST PHARMS
July 2, 2018 PMDA Astellas Pharma Inc

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Clostridium difficile infection 378.54 47.35 89 826 25014 46660133
Clostridium difficile colitis 158.80 47.35 42 873 18511 46666636
Disease recurrence 149.43 47.35 40 875 18431 46666716
Drug ineffective 61.44 47.35 70 845 677768 46007379
Pseudomembranous colitis 56.52 47.35 13 902 3182 46681965
Avian influenza 54.11 47.35 7 908 51 46685096
Treatment failure 50.67 47.35 28 887 93059 46592088
Renal graft infection 48.85 47.35 7 908 116 46685031

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Clostridium difficile infection 208.37 62.06 50 519 15733 29936176

Pharmacologic Action:

SourceCodeDescription
ATC A07AA12 ALIMENTARY TRACT AND METABOLISM
ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
INTESTINAL ANTIINFECTIVES
Antibiotics
FDA CS M0028311 Macrolides
FDA EPC N0000175431 Macrolide Antibacterial
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
CHEBI has role CHEBI:36047 antibacterial drugs
CHEBI has role CHEBI:37416 rna polymerase inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Clostridium difficile infection indication 186431008
Pseudomembranous enterocolitis indication 397683000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.95 acidic
pKa2 9.53 acidic
pKa3 11.96 acidic
pKa4 12.76 acidic
pKa5 13.32 acidic
pKa6 13.74 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
200MG DIFICID CUBIST PHARMS LLC N201699 May 27, 2011 RX TABLET ORAL Jan. 24, 2023 NEW PATIENT POPULATION
40MG/ML DIFICID CUBIST PHARMS LLC N213138 Jan. 24, 2020 RX FOR SUSPENSION ORAL Jan. 24, 2023 NEW PRODUCT
200MG DIFICID CUBIST PHARMS LLC N201699 May 27, 2011 RX TABLET ORAL July 24, 2023 PEDIATRIC EXCLUSIVITY
40MG/ML DIFICID CUBIST PHARMS LLC N213138 Jan. 24, 2020 RX FOR SUSPENSION ORAL July 24, 2023 PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
DNA-directed RNA polymerase Enzyme INHIBITOR CHEMBL CHEMBL

External reference:

IDSource
4030846 VUID
N0000182832 NUI
D09394 KEGG_DRUG
4030846 VANDF
C3162854 UMLSCUI
CHEBI:68590 CHEBI
FI8 PDB_CHEM_ID
CHEMBL1255800 ChEMBL_ID
CHEMBL445546 ChEMBL_ID
DB08874 DRUGBANK_ID
D000077732 MESH_DESCRIPTOR_UI
10034073 PUBCHEM_CID
10909 IUPHAR_LIGAND_ID
9038 INN_ID
Z5N076G8YQ UNII
1111103 RXNORM
181510 MMSL
27891 MMSL
d07778 MMSL
013814 NDDF
703664004 SNOMEDCT_US
703665003 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Dificid HUMAN PRESCRIPTION DRUG LABEL 1 52015-080 TABLET, FILM COATED 200 mg ORAL NDA 30 sections
DIFICID HUMAN PRESCRIPTION DRUG LABEL 1 52015-700 GRANULE, FOR SUSPENSION 200 mg ORAL NDA 30 sections